Compare Eli Lilly And Co (LLY) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Uranium Energy Corp — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Uranium Energy Corp trades at $9.2 (market cap $4.53B). The key difference: Eli Lilly And Co is far larger — about 229.6× Uranium Energy Corp's market cap, and Eli Lilly And Co pays a 0.59% dividend while Uranium Energy Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Uranium Energy Corp for 37 Days on average.
| LLY | UEC | |
|---|---|---|
Market Cap | $1.04T | $4.53B |
Volume | 3,064,878 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $1.28K | $20.14 |
52-Week Low | $799.57 | $9.04 |
Typical Hold Time | 93 Days | 37 Days |
Enterprise Value | $1.09T | $4.03B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
UEC trades at $9.27, down 2.11% on the day, amid a bearish technical outlook with 18 sell signals versus 2 buy signals. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and a negative net income margin of -368.62%. Recent news highlights operational expansion with two in-situ recovery mines ramping up production, supported by strong institutional analyst sentiment with 7 buy ratings and a consensus price target of $16.06.
The investment case balances Wall Street optimism against weak profitability and cash burn. Upside is driven by exposure to growing U.S. uranium demand and multi-mine expansion, but high execution risk, sustained losses, and negative operating cash flow pose significant threats to shareholder value. The stock's trajectory hinges on translating production growth into sustainable profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
